Metformin Medical Valley 500 mg Norge - norsk - Statens legemiddelverk

metformin medical valley 500 mg

medical valley invest ab - metforminhydroklorid - tablett, filmdrasjert - 500 mg

Metformin Medical Valley 850 mg Norge - norsk - Statens legemiddelverk

metformin medical valley 850 mg

medical valley invest ab - metforminhydroklorid - tablett, filmdrasjert - 850 mg

Tolvaptan Teva B.V. 30 mg / 90 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 30 mg / 90 mg

teva b.v. - tolvaptan - tablett - 30 mg / 90 mg

Tolvaptan Teva B.V. 30 mg / 60 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 30 mg / 60 mg

teva b.v. - tolvaptan - tablett - 30 mg / 60 mg

Tolvaptan Teva B.V. 45 mg / 15 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 45 mg / 15 mg

teva b.v. - tolvaptan - tablett - 45 mg / 15 mg

Orserdu Den europeiske union - norsk - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Metformin Zentiva 1000 mg Norge - norsk - Statens legemiddelverk

metformin zentiva 1000 mg

zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 1000 mg

Metformin Zentiva 500 mg Norge - norsk - Statens legemiddelverk

metformin zentiva 500 mg

zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 500 mg

Metformin Zentiva 850 mg Norge - norsk - Statens legemiddelverk

metformin zentiva 850 mg

zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 850 mg

Zydelig Den europeiske union - norsk - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.